Shares of Myovant Sciences Ltd. (MYOV) have gained more than 130% over the last 5 trading days, thanks to HERO, the Company's phase III study of once-daily, oral Relugolix in men with advanced prostate cancer.
from RTT - Biotech https://ift.tt/37z1zgl
via IFTTT
No comments:
Post a Comment